Doctor profile · Federal record
Dr. YI-BIN CHEN, MD
Hematology & Oncology Physician (CMS: MEDICAL ONCOLOGY) · Internal Medicine Physician · BOSTON, MA
- NPI 1356332639
- Accepts Medicare
- 24 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
55 FRUIT ST, WAC 625/5
BOSTON, MA 021142621
(617) 726-2066 - Mailing address
-
PO BOX 9142
CHARLESTOWN, MA 021299142
Credentials & registration
- NPI registered
- November 2005 — 21 yrs on file
- Profile last updated
- September 7, 2012
- Year of graduation
- 2002 — 24 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Massachusetts #220342
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1356332639. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
719
Distinct HCPCS
4
Medicare allowed
$101,341
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
99215 |
Established patient office or other outpatient visit, 40-54 minutes | 346 | 109 | $152 | |
99233 |
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 331 | 50 | $126 | |
99223 |
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 26 | 24 | $184 | |
99239 |
Hospital discharge day management, more than 30 minutes | 16 | 14 | $123 |
In context: peer comparison
Among 64 peers in this city , average services per provider: 129. This provider delivers 5.6× the peer median.Open Payments
Industry payments received
All-time total
$29,806
Transactions
25
Manufacturers
9
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Incyte Corporation | 13 | $8,892.45 | |
| VectivBio AG | 1 | $8,250.00 | |
| Alexion Pharmaceuticals, Inc. | 4 | $8,000.00 | |
| CSL Behring | 1 | $1,950.00 | |
| Pharmacosmos Therapeutics Inc. | 1 | $1,600.00 | |
| ZOLL Medical Corporation | 1 | $450.00 | |
| National Marrow Donor Program | 2 | $429.07 | |
| Daiichi Sankyo Inc. | 1 | $191.92 | |
| Celgene Corporation | 1 | $42.12 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
250
Patients
28
Total drug cost
$1,734,455
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Jakafi (Ruxolitinib Phosphate) | Brand | 84 | 13 | $1,341,727 |
| Acyclovir | Generic | 38 | 15 | $1,965 |
| Lorazepam | Generic | 28 | 0 | $206 |
| Sulfamethoxazole-Trimethoprim (Sulfamethoxazole/Trimethoprim) | Brand | 18 | 0 | $414 |
| Eliquis (Apixaban) | Brand | 13 | 0 | $15,002 |
| Xospata (Gilteritinib Fumarate) | Brand | 13 | 0 | $373,652 |
| Gabapentin | Generic | 12 | 0 | $118 |
| Metoprolol Succinate | Generic | 11 | 0 | $196 |
| Morphine Sulfate | Generic | 11 | 0 | $639 |
| Oxycodone Hcl | Generic | 11 | 0 | $414 |